NURO Documents déposés auprès de la SEC - NeuroMetrix, Inc.- Rapport annuel, procuration, prospectus

Statistiques de base

LEI	549300WDIIBGIRV0N856
CIK	1289850

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NeuroMetrix, Inc.

SEC Filings (Chronological Order)

Cette page fournit une liste complète et chronologique des documents déposés auprès de la SEC, à l'exclusion des documents relatifs à la participation que nous fournissons ailleurs.

May 12, 2025	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-33351 NEUROMETRIX, INC. (Exact name of registrant as specified in its c
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2025 NEUROMETRIX, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2025 NEUROMETRIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-33351 04-3308180 (State or other Jurisdiction of Incorporation) (Commission File Numb
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	POS AM	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	POS AM	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	EX-3.2	AMENDED AND RESTATED NEUROMETRIX, INC. (the “Corporation”) ARTICLE I OFFICES Echibit 3.2 AMENDED AND RESTATED BYLAWS OF NEUROMETRIX, INC. (the “Corporation”) ARTICLE I OFFICES SECTION 1.01. Registered Office. The address of the registered office of the Corporation in the State of Delaware shall be at the location originally designated upon formation of the Corporation or at a location otherwise designated by the Corporation’s Board of Directors (the “Board of Directors”).
May 2, 2025	POS AM	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	POS AM	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	POS AM	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	POS AM	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	POS AM	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	POS AM	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	EX-3.1	FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION NEUROMETRIX, INC. ARTICLE I Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEUROMETRIX, INC. ARTICLE I NAME The name of the corporation is NeuroMetrix, Inc. (hereinafter called the “Corporation”). ARTICLE II REGISTERED AGENT The address of the Corporation’s registered office in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, City of Wilmington, County of New Castle, Dela
May 2, 2025	POS AM	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	S-8 POS	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
April 30, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33
March 31, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRIX, IN
March 31, 2025	EX-4.3_19	AMENDMENT NO. 18 TO SHAREHOLDER RIGHTS AGREEMENT Exhibit 4.3.19 AMENDMENT NO. 18 TO SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 18 to Shareholder Rights Agreement (the “Amendment”), dated as of March 28, 2025, by and between NeuroMetrix, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (f/k/a/ American Stock Transfer & Trust Company, LLC) (the “Rights Agent”), amends that certain Shareholder Rights Agreement, dat
March 31, 2025	EX-10.16	ASSET PURCHASE AGREEMENT NEUROMETRIX INC. FUKUDA DENSHI CO., LTD. dated as of January 16, 2025 Exhibit 10.16 ASSET PURCHASE AGREEMENT between NEUROMETRIX INC. and FUKUDA DENSHI CO., LTD. dated as of January 16, 2025 1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this “Agreement”), dated as of January16, 2025, is entered into between NeuroMetrix Inc., a Delaware corporation (“Seller”) with its principal place of business at 4b Gill Street, Woburn, MA 01801 U.S.A., and Fukuda Densh
March 31, 2025	EX-19.1	NEUROMETRIX, INC. Statement of Company Policy on Insider Trading and Disclosure Exhibit 19.1 NEUROMETRIX, INC. Statement of Company Policy on Insider Trading and Disclosure This memorandum sets forth the policy of NeuroMetrix, Inc. (the “Company”) regarding insider trading and the disclosure of information concerning the Company. This Statement of Company Policy on Insider Trading and Disclosure (the “Insider Trading Statement”) is applicable to all directors, officers and em
March 25, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2025 NEUROMETRIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File N
February 14, 2025	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
January 30, 2025	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
January 30, 2025	EX-FILING FEES	CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) NeuroMetrix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) NeuroMetrix, Inc.
January 23, 2025	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Num
December 30, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
December 19, 2024	EX-1	Schedule A Schedule A Transactions in Securities of the Issuer During the Past Sixty Days Avg. Number of Price per Nature of Transaction Shares Share ($) Date Sale of Common Stock 30,623 $4.21 12/17/2024 Sale of Common Stock 35,100 $4.05 12/18/2024
December 17, 2024	EX-10.1	Form of Voting and Support Agreement, dated as of December 17, 2024, by and among electroCore, Inc. and the stockholders named therein Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (hereinafter referred to as this “Agreement”), dated as of December 17, 2024, is by and between electroCore, Inc., a Delaware corporation (“Parent”), and each of the undersigned Persons identified on Schedule I attached hereto (each, a “Stockholder”). WHEREAS, each Stockholder is, as of the date hereof, the record or benef
December 17, 2024	EX-10.2	Amended and Restated Management Retention and Incentive Plan Exhibit 10.2 NEUROMETRIX, INC. Amended and Restated Management Retention and Incentive Plan 1.              Purpose of the Plan. The purpose of this Management Retention and Incentive Plan (the “Plan”) is to provide the executive officers and certain other key employees of NeuroMetrix, Inc., a Delaware corporation (the “Company”), listed on Schedule A hereto (the “Participants,” and each, a “Parti
December 17, 2024	EX-10.2	Amended and Restated Management Retention and Incentive Plan Exhibit 10.2 NEUROMETRIX, INC. Amended and Restated Management Retention and Incentive Plan 1.              Purpose of the Plan. The purpose of this Management Retention and Incentive Plan (the “Plan”) is to provide the executive officers and certain other key employees of NeuroMetrix, Inc., a Delaware corporation (the “Company”), listed on Schedule A hereto (the “Participants,” and each, a “Parti
December 17, 2024	EX-2.1	Agreement and Plan of Merger, dated as of December 17, 2024, by and among electroCore, Inc., Nexus Merger Sub Inc., and NeuroMetrix, Inc.   Exhibit 2.1   AGREEMENT AND PLAN OF MERGER   BY AND AMONG   ELECTROCORE, INC.   NEXUS MERGER SUB INC.   and   NEUROMETRIX, INC.   DATED AS OF   DECEMBER 17, 2024         TABLE OF CONTENTS   Article I THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Conversion of Shares of Company Stock 3 Section 1.3 Surrender and Payment 3 Section 1.4 Dissenting Shares 6 Section 1.5 Company Equity Awards and Co
December 17, 2024	EX-2.1	Agreement and Plan of Merger, dated as of December 17, 2024, by and among electroCore, Inc., Nexus Merger Sub Inc., and NeuroMetrix, Inc.   Exhibit 2.1   AGREEMENT AND PLAN OF MERGER   BY AND AMONG   ELECTROCORE, INC.   NEXUS MERGER SUB INC.   and   NEUROMETRIX, INC.   DATED AS OF   DECEMBER 17, 2024         TABLE OF CONTENTS   Article I THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Conversion of Shares of Company Stock 3 Section 1.3 Surrender and Payment 3 Section 1.4 Dissenting Shares 6 Section 1.5 Company Equity Awards and Co
December 17, 2024	EX-4.1	Amendment No. 17 to Shareholder Rights Agreement by and between NeuroMetrix, Inc. and Equiniti Trust Company, LLC, as Rights Agent, dated December 17, 2024 Exhibit 4.1 AMENDMENT NO. 17 TO SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 17 to Shareholder Rights Agreement (the “Amendment”), dated as of December 17, 2024, by and between NeuroMetrix, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (f/k/a/ American Stock Transfer & Trust Company, LLC) (the “Rights Agent”), amends that certain Shareholder Rights Agreement, dat
December 17, 2024	EX-4.1	Amendment No. 17 to Shareholder Rights Agreement by and between NeuroMetrix, Inc. and Equiniti Trust Company, LLC, as Rights Agent, dated December 17, 2024 Exhibit 4.1 AMENDMENT NO. 17 TO SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 17 to Shareholder Rights Agreement (the “Amendment”), dated as of December 17, 2024, by and between NeuroMetrix, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (f/k/a/ American Stock Transfer & Trust Company, LLC) (the “Rights Agent”), amends that certain Shareholder Rights Agreement, dat
December 17, 2024	EX-99.1	Press Release, dated December 17, 2024 Exhibit 99.1 NeuroMetrix to be Acquired by electroCore NeuroMetrix shareholders to receive cash and Contingent Value Rights WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) - NeuroMetrix, Inc. (“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial stage bioelectronic medic
December 17, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
December 17, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 NEUROMETRIX, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2024 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
December 17, 2024	EX-99.1	NeuroMetrix to be Acquired by electroCore NeuroMetrix shareholders to receive cash and Contingent Value Rights Exhibit 99.1 NeuroMetrix to be Acquired by electroCore NeuroMetrix shareholders to receive cash and Contingent Value Rights WOBURN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) - NeuroMetrix, Inc. (“NeuroMetrix” or the “Company”) (Nasdaq: NURO) today announced it has entered into a definitive merger agreement whereby electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial stage bioelectronic medic
December 17, 2024	EX-10.1	Form of Voting and Support Agreement, dated as of December 17, 2024, by and among electroCore, Inc. and the stockholders named therein Exhibit 10.1 VOTING AND SUPPORT AGREEMENT This VOTING AND SUPPORT AGREEMENT (hereinafter referred to as this “Agreement”), dated as of December 17, 2024, is by and between electroCore, Inc., a Delaware corporation (“Parent”), and each of the undersigned Persons identified on Schedule I attached hereto (each, a “Stockholder”). WHEREAS, each Stockholder is, as of the date hereof, the record or benef
November 5, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Num
November 5, 2024	EX-99.1	NeuroMetrix Reports Q3 2024 Business Highlights Company Continues to Pursue Review of Strategic Alternatives NeuroMetrix Reports Q3 2024 Business Highlights Company Continues to Pursue Review of Strategic Alternatives WOBURN, Mass.
November 5, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROM
September 27, 2024	SC 13G	NURO / NeuroMetrix, Inc. / Radoff Bradley Louis - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 NeuroMetrix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 641255880 (CUSIP Number) Septem
September 27, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 ex991to13g09076064092724.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated September 27, 2024, with respect to the Common Stock, $0.0001 par value per share, of NeuroMetrix, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned purs
August 6, 2024	EX-99.1	NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options WOBURN, Mass.
August 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Numbe
August 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRIX
May 31, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 4B Gill Street, Woburn, Massachusetts 01801 (Address of principal exe
May 31, 2024	EX-1.01	NeuroMetrix, Inc. Conflict Minerals Report For the Year Ended December 31, 2023 Exhibit 1.01 NeuroMetrix, Inc. Conflict Minerals Report For the Year Ended December 31, 2023 Company Overview NeuroMetrix, Inc. (the “Company”) develops and markets medical devices. Its products include: 1.The Quell Pain Management System, an OTC wearable device designed for relief of chronic, intractable pain. 2.The NC-stat DPNCheck test to evaluate systemic neuropathies such as diabetic peripher
May 15, 2024	S-8	As filed with the Securities and Exchange Commission on May 15, 2024 As filed with the Securities and Exchange Commission on May 15, 2024 Registration No.
May 15, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeuroMetrix, Inc.
May 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRI
May 15, 2024	EX-10.2	Shai N. Gozani, M.D., PhD Employment Agreement – December 30, 2020 Addendum – Other Terms April 25, 2024 Shai N. Gozani, M.D., PhD Employment Agreement – December 30, 2020 Addendum – Other Terms On behalf of the Board of Directors of NeuroMetrix, Inc., the Compensation Committee of the Board confirms the following modification to the terms of your employment: “Other Terms – This agreement is extended for an additional term of one (1) year beyond the initial term of three (3) years comm
May 15, 2024	EX-10.3	Thomas T. Higgins Employment Agreement – December 30, 2020 April 25, 2024 Thomas T. Higgins Employment Agreement – December 30, 2020 Addendum On behalf of the Board of Directors of NeuroMetrix, Inc., the Compensation Committee of the Board confirms the following modification to the terms of your employment: “Other terms – This agreement is extended for an additional term of one (1) year beyond the initial term of three (3) years commencing on January 1, 2
May 1, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2024 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Numbe
April 19, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 NEUROMETRIX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File N
April 19, 2024	EX-10.1	INDEMNIFICATION AGREEMENT INDEMNIFICATION AGREEMENT This Agreement made and entered into this day of , (the “Agreement”), by and between NeuroMetrix, Inc.
April 19, 2024	EX-99.1	NeuroMetrix Announces Steps Taken to Enhance Shareholder Value NeuroMetrix Announces Steps Taken to Enhance Shareholder Value •Joshua S. Horowitz joins Board of Directors •At-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) - NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital.
April 12, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
April 5, 2024	EX-10.1	Shai N. Gozani, M.D., PhD Employment Agreement – December 30, 2020 April 4, 2024 Shai N. Gozani, M.D., PhD Employment Agreement – December 30, 2020 Addendum On behalf of the Board of Directors of NeuroMetrix, Inc., the Compensation Committee of the Board confirms the following modification to the terms of your employment: “Base Salary – your annual salary (“Base Salary”), currently in the amount of $458,575, remains subject to periodic review and adjustment at th
April 5, 2024	EX-10.2	Thomas T. Higgins Employment Agreement – December 30, 2020 April 5, 2024 Thomas T. Higgins Employment Agreement – December 30, 2020 Addendum On behalf of the Board of Directors of NeuroMetrix, Inc., the Compensation Committee of the Board confirms the following modification to the terms of your employment: “Base Salary – your annual salary (“Base Salary”), currently in the amount of $359,125, remains subject to periodic review and adjustment at the discre
April 5, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 NEUROMETRIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
March 27, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
March 4, 2024	SC 13D/A	NURO / NeuroMetrix, Inc. / RS Fund LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* NeuroMetrix, Inc. (NURO) (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 641255880 (CUSIP Number) Ryan Siegal, 420 E 51st Street, Unit 8d, New York, New York 10022 215-939-0313 (Name, Address and Telephone Number
March 1, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRIX, IN
March 1, 2024	EX-97	NeuroMetrix, Inc. Compensation Clawback Policy Adopted October 23, 2023 NeuroMetrix, Inc. Compensation Clawback Policy Adopted October 23, 2023 Purpose The Board of Directors (the “Board”) of NeuroMetrix, Inc. (the “Corporation”) believes that it is in the best interest of the Corporation and its shareholders to maintain a culture that emphasizes integrity and accountability and that reinforces the Corporation’s compensation philosophy. The Board has therefore adopted
February 27, 2024	SC 13D	NURO / NeuroMetrix, Inc. / Fields ephraim - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* NEUROMETRIX, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 641255880 (CUSIP Number) Ephraim Fields c/o Echo Lake Capital 265 East 66th Street – 42nd Floor NY, NY 10065 (917) 620-8421 Name, Address and Telep
February 27, 2024	EX-4.1	Amendment No. 16 to Shareholder Rights Agreement, dated February 20, 2024, between NeuroMetrix, Inc. and Equiniti Trust Company, LLC, as Rights Agent AMENDMENT NO. 16 TO SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 16 to Shareholder Rights Agreement (the “Amendment”), dated as of February 20, 2024, by and between NeuroMetrix, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (f/k/a/ American Stock Transfer & Trust Company, LLC) (the “Rights Agent”), amends that certain Shareholder Rights Agreement, dated as of Mar
February 27, 2024	EX-4.1	AMENDMENT NO. 16 TO SHAREHOLDER RIGHTS AGREEMENT AMENDMENT NO. 16 TO SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 16 to Shareholder Rights Agreement (the “Amendment”), dated as of February 20, 2024, by and between NeuroMetrix, Inc., a Delaware corporation (the “Company”), and Equiniti Trust Company, LLC (f/k/a/ American Stock Transfer & Trust Company, LLC) (the “Rights Agent”), amends that certain Shareholder Rights Agreement, dated as of Mar
February 27, 2024	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 NEUROMETRIX, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 NEUROMETRIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission F
February 27, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 NEUROMETRIX, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 NEUROMETRIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission Fil
February 26, 2024	SC 13D	NURO / NeuroMetrix, Inc. / RS Fund LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* NeuroMetrix, Inc. (NURO) (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 641255880 (CUSIP Number) Ryan Siegal, 420 E 51st Street, Unit 8d, New York, New York 10022 215-939-0313 (Name, Address and Telephone Number
February 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
February 22, 2024	EX-99.1	NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights WOBURN, Mass., February 22, 2024 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. "Quell® F
November 20, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 20, 2023 NeuroMetrix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation or organization)
November 20, 2023	EX-99.1	NeuroMetrix Announces One-for-Eight Reverse Stock Split NeuroMetrix Announces One-for-Eight Reverse Stock Split WOBURN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) - NeuroMetrix, Inc. (NASDAQ: NURO) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on November 21, 2023 (the “Effective Time”). The shares underlying the Company's outstanding options will also be adjusted accordingly. The reverse stock s
November 20, 2023	EX-3.1	NeuroMetrix, Inc. CERTIFICATE OF AMENDMENT TO EFFECT REVERSE STOCK SPLIT NeuroMetrix, Inc. CERTIFICATE OF AMENDMENT TO EFFECT REVERSE STOCK SPLIT NeuroMetrix, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1.The name of the Corporation is NeuroMetrix, Inc. 2.The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware (the “Sec
October 26, 2023	EX-99.1	NeuroMetrix Reports Q3 2023 Business Highlights NeuroMetrix Reports Q3 2023 Business Highlights WOBURN, Mass., October 26, 2023 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. "We continue to
October 26, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROM
October 26, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Num
October 20, 2023	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 19, 2023 NeuroMetrix, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation or organization)
September 11, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
August 30, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
August 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Numbe
July 27, 2023	EX-FILING FEES	Calculation of Filing Fee Table Form S-8 (Form Type) NeuroMetrix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeuroMetrix, Inc.
July 27, 2023	S-8	As filed with the Securities and Exchange Commission on July 27, 2023 As filed with the Securities and Exchange Commission on July 27, 2023 Registration No.
July 27, 2023	EX-99.1	NeuroMetrix Reports Q2 2023 Business Highlights NeuroMetrix Reports Q2 2023 Business Highlights WOBURN, Mass., July 27, 2023 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and six months period ended June 30, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. "We have taken an impor
July 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number
July 27, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRIX
May 31, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 4B Gill Street, Woburn, Massachusetts 01801 (Address of principal exe
May 31, 2023	EX-1.01	NeuroMetrix, Inc. Conflict Minerals Report For the Year Ended December 31, 2022 Exhibit 1.01 NeuroMetrix, Inc. Conflict Minerals Report For the Year Ended December 31, 2022 Company Overview NeuroMetrix, Inc. (the “Company”) develops and markets medical devices. Its products include: 1.The Quell Pain Management System, an OTC wearable device designed for relief of chronic, intractable pain. 2.The NC-stat DPNCheck test to evaluate systemic neuropathies such as diabetic peripher
May 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRI
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number)
May 3, 2023	EX-99.1	NeuroMetrix Reports Q1 2023 Financial Results NeuroMetrix Reports Q1 2023 Financial Results WOBURN, Mass., May 3, 2023 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices. Q1 Highl
May 3, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number)
March 30, 2023	DEF 14A	Definitive Proxy Statement on Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
March 22, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRIX, IN
March 10, 2023	EX-4.1	Amendment No. 15 to Shareholder Rights Agreement, dated March 6, 2023, between NeuroMetrix, Inc. and American Stock Transfer & Trust Company, as Rights Agent Exhibit 4.1 AMENDMENT NO. 15 TO SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 15 to Shareholder Rights Agreement (the “Amendment”), dated as of March 6, 2023, by and between NeuroMetrix, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC (the “Rights Agent”), amends that certain Shareholder Rights Agreement, dated as of March 7, 2007, as previously ame
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 NEUROMETRIX, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 NEUROMETRIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
February 23, 2023	EX-99.1	NeuroMetrix Reports Q4 and Full Year 2022 Financial Results NeuroMetrix Reports Q4 and Full Year 2022 Financial Results WOBURN, Mass., February 23, 2023 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative n
February 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
February 13, 2023	EX-99.A	JOINT FILING UNDERTAKING EX-99.A EXHIBIT A JOINT FILING UNDERTAKING The undersigned, being authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule, as it may be amended, jointly on behalf of each of such parties. Dated: February 13,
February 13, 2023	SC 13G/A	NURO / Neurometrix Inc / Topline Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 d417531dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) NeuroMetrix, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 641255807 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of Statement) Check the appropriate box to designate
October 20, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROM
October 20, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Num
October 20, 2022	EX-99.1	NeuroMetrix Reports Q3 2022 Financial Results NeuroMetrix Reports Q3 2022 Financial Results WOBURN, Mass., October 20, 2022 (Globe Newswire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-inv
August 31, 2022	424B5	NeuroMetrix, Inc. Up to $7,600,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-260438 AMENDMENT NO. 1 DATED AUGUST 31, 2022 to Prospectus Supplement dated November 5, 2021 (To Prospectus dated November 5, 2021) NeuroMetrix, Inc. Up to $7,600,000 Common Stock This Amendment No. 1 to Prospectus Supplement (this ?Amendment?) amends our prospectus supplement dated November 5, 2021 (the ?Prospectus Supplement?). This Amendment
July 21, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2022 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number
July 21, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRIX
July 21, 2022	EX-99.1	NeuroMetrix Reports Q2 2022 Financial Results Exhibit 99.1 NeuroMetrix Reports Q2 2022 Financial Results WOBURN, Mass., July 21, 2022 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative no
June 28, 2022	EX-99.1	NeuroMetrix Appoints Brad Fluegel to its Board of Directors Exhibit 99.1 NeuroMetrix Appoints Brad Fluegel to its Board of Directors WOBURN, Mass., June 28, 2022 (GLOBE NEWSWIRE) - NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022. Mr. Fluegel has a broad commercial and advisory background with concentrated industry experience in healthcare and medical technology.
June 28, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 NEUROMETRIX, INC. (Exact name of registrant as specified in its charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
May 31, 2022	EX-1.01	NeuroMetrix, Inc. Conflict Minerals Report For the Year Ended December 31, 2021 EX-1.01 2 sd2021confminmay2022ex101.htm EX-1.01 Exhibit 1.01 NeuroMetrix, Inc. Conflict Minerals Report For the Year Ended December 31, 2021 Company Overview NeuroMetrix, Inc. (the “Company”) develops and markets medical devices. Its products include: 1.The Quell Pain Management System, an OTC wearable device designed for relief of chronic, intractable pain. 2.The NC-stat DPNCheck test to evaluate
May 31, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 4B Gill Street, Woburn, Massachusetts 01801 (Address of principal exe
May 19, 2022	EX-99.1+	NeuroMetrix, Inc. Employee Stock Purchase Plan, as amended Exhibit 99.1 NeuroMetrix, Inc. EMPLOYEE STOCK PURCHASE PLAN The following constitute the provisions of the Employee Stock Purchase Plan (the ?Plan?) of NeuroMetrix, Inc. (the ?Company?). 1. Purpose. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company. It is the intention of the Company to have th
May 19, 2022	S-8	As filed with the Securities and Exchange Commission on May 19, 2022 As filed with the Securities and Exchange Commission on May 19, 2022 Registration No.
May 19, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) NeuroMetrix, Inc.
May 19, 2022	EX-99.3+	Form of Stock Option Agreement under 2022 Equity Incentive Plan Exhibit 99.3 NEUROMETRIX, INC. Stock Option Grant Notice Stock Option Grant under the Company?s 2022 Equity Incentive Plan Name: Grant Number: Grant Date: Vest Commencement Date: Grant Type: Grant Shares: Exercise Price: Expiration Date: Vesting Schedule: This Option shall become exercisable (and the Shares issued upon exercise shall be vested) as follows provided the Participant is an Employee, D
May 19, 2022	EX-99.2+	NeuroMetrix, Inc. 2022 Equity Incentive Plan Exhibit 99.2 NEUROMETRIX, INC. 2022 EQUITY INCENTIVE PLAN 1.DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this NeuroMetrix, Inc. 2022 Equity Incentive Plan, have the following meanings: ?Administrator? means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which case the term ?Adminis
May 19, 2022	EX-99.4+	Form of Restricted Stock Unit Agreement under 2022 Equity Incentive Plan Exhibit 99.4 NEUROMETRIX, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Grant under the Company?s 2022 Equity Incentive Plan Name: Grant Number: Grant Date: Grant Type: Grant Shares: Vesting of Award: This Restricted Stock Unit Award shall vest as follows provided the Participant is an Employee, director or Consultant of the Company or of an Affiliate on the applicable vestin
May 3, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number)
April 26, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Numbe
April 26, 2022	EX-99.1	NeuroMetrix Reports Q1 2022 Financial Results NeuroMetrix Reports Q1 2022 Financial Results WOBURN, Mass., April 26, 2022 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices. Highl
April 26, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRI
March 24, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 neurometrixinc-proxystatem.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissio
February 14, 2022	EX-99.A	JOINT FILING UNDERTAKING EXHIBIT A JOINT FILING UNDERTAKING The undersigned, being authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule, as it may be amended, jointly on behalf of each of such parties.
February 14, 2022	SC 13G/A	NURO / Neurometrix Inc / Topline Capital Management, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) NeuroMetrix, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 641255807 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
January 28, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRIX, IN
January 28, 2022	EX-4.1	DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 NeuroMetrix, Inc.
January 28, 2022	EX-10.13.2	Employment Agreement NEUROMetrix December 30, 2020 Thomas T. Higgins Dear Mr. Higgins: Employment Agreement On behalf of NeuroMetrix, Inc. (the ?Company?) and the Board of Directors, the Compensation Committee of the Board of Directors confirms your employment under the following terms: ?Title & Responsibilities: Senior Vice President, Chief Financial Officer overseeing the Company?s Finance Department, Investor Relat
January 28, 2022	EX-10.12.2	Employment Agreement NEUROMetrix December 30, 2020 Shai N. Gozani, M.D., Ph.D. Dear Dr. Gozani: Employment Agreement On behalf of NeuroMetrix, Inc. (the ?Company?) and the Board of Directors, the Compensation Committee of the Board of Directors confirms your employment under the following terms: ?Title & Responsibilities: President, Chief Executive Officer and Chairman of the Board of Directors. In this position, you
January 27, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Num
January 27, 2022	EX-99.1	NeuroMetrix Reports Q4 and Full Year 2021 Financial Results NeuroMetrix Reports Q4 and Full Year 2021 Financial Results WOBURN, Mass., January 27, 2022 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative no
December 10, 2021	EX-3.1	Amended and Restated Bylaws of NeuroMetrix, Inc. AMENDED AND RESTATED BY-LAWS OF NEUROMETRIX, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may subsequently be c
December 10, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Num
December 3, 2021	EX-16.1	December 3, 2021 Exhibit 16.1 December 3, 2021 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentlemen: We are the former independent registered public accounting firm for NeuroMetrix, Inc. (the ?Company?). We have read the Company?s disclosure set forth in Item 4.01 ?Changes in Registrant?s Certifying Accountant? of the Company?s Current Report on Form 8-K dated December
December 3, 2021	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Num
November 2, 2021	CORRESP	NEUROMETRIX, INC. 4B Gill Street Woburn, Massachusetts 01801 NEUROMETRIX, INC. 4B Gill Street Woburn, Massachusetts 01801 November 2, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart RE: NeuroMetrix, Inc. Registration Statement on Form S-3 Filed October 22, 2021 File No. 333-260438 Acceleration Request Dear Ms. Ansart: With respect to the above-referenc
October 22, 2021	S-3	As filed with the Securities and Exchange Commission on October 22, 2021 As filed with the Securities and Exchange Commission on October 22, 2021 Registration No.
October 22, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Num
October 22, 2021	EX-1.2	At Market Issuance Sales Agreement dated October 22, 2021 by and between NeuroMetrix, Inc. and Ladenburg Thalmann & Co. Inc. (filed as Exhibit 1.2 to the Registrant’s Form S-3 filed on October 22, 2021 and incorporated in this document by reference) NeuroMetrix, Inc. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement October 22, 2021 Ladenburg Thalmann & Co. Inc. 277 Park Avenue, 26th Floor New York, NY 10172 Ladies and Gentlemen: NeuroMetrix, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Ladenburg Thalmann & Co. Inc (the ?Agent?) as follows: 1.Issuance and Sale of Shares. The Company agrees th
October 21, 2021	EX-99.1	NeuroMetrix Reports Q3 2021 Financial Results NeuroMetrix Reports Q3 2021 Financial Results WOBURN, Mass., October 21, 2021 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. Highlights: ?Revenue of $2.1 million was up
October 21, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROM
October 21, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Num
August 13, 2021	424B5	NEUROMETRIX, INC. Up to $14,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-229349 PROSPECTUS SUPPLEMENT (To Prospectus dated March 8, 2019) NEUROMETRIX, INC. Up to $14,000,000 Common Stock This prospectus supplement amends and supplements certain information contained in the prospectus supplements dated February 19, 2020, April 24, 2020, May 20, 2020, June 1, 2020, June 5, 2020, June 11, 2020, April
August 13, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Numb
July 22, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRIX
July 22, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number
July 22, 2021	EX-4.1	Amendment No. 14 to Shareholder Rights Agreement, dated July 20, 2021, between NeuroMetrix, Inc. and American Stock Transfer & Trust Company, as Rights Agent AMENDMENT NO. 14 TO SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 14 to Shareholder Rights Agreement (the ?Amendment?), dated as of July 20, 2021, by and between NeuroMetrix, Inc., a Delaware corporation (the ?Company?), and American Stock Transfer & Trust Company, LLC (the ?Rights Agent?), amends that certain Shareholder Rights Agreement, dated as of March 7, 2007, as previously amended, betwee
July 22, 2021	EX-10.1	EXECUTION NY: 1295413-1 TERMINATION AGREEMENT This Termination Agreement (the “Termination Agreement”) is made as of June 30, 2021, (the “Effective Date”) by and between: (1) GSK Consumer Healthcare SARL, formerly known as GSK Consumer Healthcare S.A EXECUTION NY: 1295413-1 TERMINATION AGREEMENT This Termination Agreement (the ?Termination Agreement?) is made as of June 30, 2021, (the ?Effective Date?) by and between: (1) GSK Consumer Healthcare SARL, formerly known as GSK Consumer Healthcare S.
July 22, 2021	EX-99.1	NeuroMetrix Reports Q2 2021 Financial Results NeuroMetrix Reports Q2 2021 Financial Results WOBURN, Mass., July 22, 2021 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. Highlights: ?Revenue of $2.2 million improved 63% f
June 30, 2021	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number
June 25, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number
June 25, 2021	424B5	NEUROMETRIX, INC. Up to $2,400,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-229349 PROSPECTUS SUPPLEMENT (To Prospectus dated March 8, 2019) NEUROMETRIX, INC. Up to $2,400,000 Common Stock This prospectus supplement amends and supplements certain information contained in the prospectus supplements dated February 19, 2020, April 24, 2020, May 20, 2020, June 1, 2020, June 5, 2020, June 11, 2020 and April 15, 2021 to the
June 14, 2021	EX-1.01	NeuroMetrix, Inc. Conflict Minerals Report For the Year Ended December 31, 2020 EX-1.01 2 sd2020confminmay2021ex101.htm EX-1.01 Exhibit 1.01 NeuroMetrix, Inc. Conflict Minerals Report For the Year Ended December 31, 2020 Company Overview NeuroMetrix, Inc. (the “Company”) develops and markets medical devices. Its products include: 1.The Quell Pain Management System, an OTC wearable device designed for relief of chronic, intractable pain. 2.The NC-stat DPNCheck test to evaluate
June 14, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 4B Gill Street, Woburn, Massachusetts 01801 (Address of principal exe
June 11, 2021	SC 13G/A	NURO / Neurometrix Inc / Topline Capital Management, LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) NeuroMetrix, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 641255807 (CUSIP Number) June 9, 2021 (Date of Event Which Requires Filing of Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
June 11, 2021	EX-3.1	THIRD AMENDED AND RESTATED NEUROMETRIX, INC. (the “Corporation”) ARTICLE I THIRD AMENDED AND RESTATED BY-LAWS OF NEUROMETRIX, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and place may subsequentl
June 11, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number
June 11, 2021	EX-99.A	JOINT FILING UNDERTAKING EXHIBIT A JOINT FILING UNDERTAKING The undersigned, being authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule, as it may be amended, jointly on behalf of each of such parties.
June 10, 2021	SC 13G	NURO / Neurometrix Inc / Topline Capital Management, LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) NeuroMetrix, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 641255807 (CUSIP Number) June 7, 2021 (Date of Event Which Requires Filing of Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is
June 10, 2021	EX-99.A	JOINT FILING UNDERTAKING EXHIBIT A JOINT FILING UNDERTAKING The undersigned, being authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule, as it may be amended, jointly on behalf of each of such parties.
May 26, 2021	S-8	As filed with the Securities and Exchange Commission on May 26, 2021 As filed with the Securities and Exchange Commission on May 26, 2021 REGISTRATION NO.
May 11, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number)
April 27, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Numbe
April 22, 2021	EX-99.1	NeuroMetrix Reports Q1 2021 Financial Results Exhibit 99.1 NeuroMetrix Reports Q1 2021 Financial Results WOBURN, Mass., April 22, 2021 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. Q1 2021 Highlights: •Revenue of $2.2
April 22, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRI
April 22, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Numbe
April 15, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Numbe
April 15, 2021	424B5	NEUROMETRIX, INC. Up to $3,850,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-229349 PROSPECTUS SUPPLEMENT (To Prospectus dated March 8, 2019) NEUROMETRIX, INC. Up to $3,850,000 Common Stock This prospectus supplement amends and supplements certain information contained in the prospectus supplements dated February 19, 2020, April 24, 2020, May 20, 2020,June 1, 2020, June 5, 2020 and June 11, 2020 to the prospectus dated
March 16, 2021	DEF 14A	Proxy Statement for our Annual Meeting of Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
February 26, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
February 26, 2021	EX-10.1	NEUROMETRIX, INC. Amended and Restated Management Retention and Incentive Plan NEUROMETRIX, INC. Amended and Restated Management Retention and Incentive Plan 1.Purpose of the Plan. The purpose of this Management Retention and Incentive Plan (the ?Plan?) is to provide the executive officers and certain other key employees of NeuroMetrix, Inc., a Delaware corporation (the ?Company?), listed on Schedule A hereto (the ?Participants,? and each, a ?Participant?) with consideration
January 29, 2021	EX-4.3.14	Amendment No. 13 to Shareholder Rights Agreement, dated January 25, 2021, between NeuroMetrix, Inc. and American Stock Transfer & Trust Company, as Rights Agent EX-4.3.14 3 a10k2020exhibit4314.htm EX-4.3.14 AMENDMENT NO. 13 TO SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 13 to Shareholder Rights Agreement (the “Amendment”), dated as of January 28, 2021, by and between NeuroMetrix, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC (the “Rights Agent”), amends that certain Shareholder Rights Agreement, dated a
January 29, 2021	EX-4.1	DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, NeuroMetrix, Inc.
January 29, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRIX, IN
January 28, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2021 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Num
January 28, 2021	EX-99.1	NeuroMetrix Reports Q4 and Full Year 2020 Financial Results NeuroMetrix Reports Q4 and Full Year 2020 Financial Results WOBURN, Mass., January 28, 2021 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2020. The Company is focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving
December 31, 2020	EX-10.13.5	Employment Agreement NEUROMetrix December 30, 2020 Shai N. Gozani, M.D., Ph.D. 1 Unity Street Newton, MA 02466 Dear Dr. Gozani: Employment Agreement On behalf of NeuroMetrix, Inc. (the “Company”) and the Board of Directors, the Compensation Committee of the Board of Directors confirms your employment under the following terms: •Title & Responsibilities: President, Chief Executive Officer and Chairman of the Board of D
December 31, 2020	EX-10.14.4	Employment Agreement NEUROMetrix December 30, 2020 Thomas T. Higgins 90 Carlton Street Brookline, MA 02446 Dear Mr. Higgins: Employment Agreement On behalf of NeuroMetrix, Inc. (the “Company”) and the Board of Directors, the Compensation Committee of the Board of Directors confirms your employment under the following terms: •Title & Responsibilities: Senior Vice President, Chief Financial Officer overseeing the Compan
December 31, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
October 22, 2020	EX-99.1	NeuroMetrix Reports Q3 2020 Financial Results NeuroMetrix Reports Q3 2020 Financial Results WOBURN, Mass., October 22, 2020 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020. The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health conditions. Q3 2020 Highlights: • Revenue of $2.0 m
October 22, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Num
October 22, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROM
July 23, 2020	10-Q	Quarterly Report - 10-Q 10-Q 1 a10q6302020document.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi
July 23, 2020	EX-99.1	NeuroMetrix Reports Q2 2020 Financial Results NeuroMetrix Reports Q2 2020 Financial Results WOBURN, Mass., July 23, 2020 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020. The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health conditions. Q2 2020 Highlights: • Total revenue of $1.4 mil
July 23, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number
June 11, 2020	424B5	NEUROMETRIX, INC. Up to $113,000 Common Stock 424B5 1 atmprospectus20200611.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-229349 PROSPECTUS SUPPLEMENT (To Prospectus dated March 8, 2019) NEUROMETRIX, INC. Up to $113,000 Common Stock This prospectus supplement amends and supplements certain information contained in the prospectus supplements dated February 19, 2020, April 24, 2020, May 20, 2020,June 1, 2020 and June 5, 2020 t
June 11, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number
June 5, 2020	424B5	NEUROMETRIX, INC. Up to $184,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-229349 PROSPECTUS SUPPLEMENT (To Prospectus dated March 8, 2019) NEUROMETRIX, INC. Up to $184,000 Common Stock This prospectus supplement amends and supplements certain information contained in the prospectus supplements dated February 19, 2020, April 24, 2020, May 20, 2020 and June 1, 2020 to the prospectus dated March 8, 2019, relating to the
June 5, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number)
June 1, 2020	424B5	NEUROMETRIX, INC. Up to $315,000 Common Stock 424B5 1 neurometrix-atmprospectuss.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-229349 PROSPECTUS SUPPLEMENT (To Prospectus dated March 8, 2019) NEUROMETRIX, INC. Up to $315,000 Common Stock This prospectus supplement amends and supplements certain information contained in the prospectus supplements dated February 19, 2020, April 24, 2020 and May 20, 2020 to the prospectus dated
June 1, 2020	8-K	Financial Statements and Exhibits, Other Events 8-K 1 neurometrix-form8xkrefilin.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction o
May 28, 2020	SD	- SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 4B Gill Street, Woburn, Massachusetts 01801 (Address of principal exe
May 28, 2020	EX-1.01	NeuroMetrix, Inc. Conflict Minerals Report For the Year Ended December 31, 2019 Exhibit 1.01 NeuroMetrix, Inc. Conflict Minerals Report For the Year Ended December 31, 2019 Company Overview NeuroMetrix, Inc. (the “Company”) develops and markets medical devices. Its products include: • The Quell Pain Management System, an OTC wearable device designed for relief of chronic, intractable pain. • The NC-stat DPNCheck test to evaluate systemic neuropathies such as diabetic peripher
May 20, 2020	424B5	NEUROMETRIX, INC. Up to $570,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-229349 PROSPECTUS SUPPLEMENT (To Prospectus dated March 8, 2019) NEUROMETRIX, INC. Up to $570,000 Common Stock This prospectus supplement amends and supplements certain information contained in the prospectus supplements dated February 19, 2020 and April 24, 2020 to the prospectus dated March 8, 2019, relating to the offer and sale of shares of
May 20, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number)
May 7, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number)
April 30, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Numbe
April 30, 2020	EX-10.2	EX-10.2 exhibit102neurometrixinc
April 30, 2020	EX-10.1	EX-10.1 neurometrixinc4963sbanot
April 28, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Numbe
April 24, 2020	8-K	Financial Statements and Exhibits, Other Events 8-K 1 neurometrix-form8xkrefilin.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction
April 24, 2020	424B5	NEUROMETRIX, INC. Up to $1,100,000 Common Stock 424B5 1 neurometrix-atmprospectuss.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-229349 PROSPECTUS SUPPLEMENT (To Prospectus dated March 8, 2019) NEUROMETRIX, INC. Up to $1,100,000 Common Stock This prospectus supplement amends and supplements certain information contained in the prospectus supplement dated February 19, 2020 to the prospectus dated March 8, 2019, relating to the
April 23, 2020	10-Q	Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRI
April 23, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a20200331-form8xkq1earning.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction
April 23, 2020	EX-99.1	NeuroMetrix Reports Q1 2020 Financial Results EX-99.1 2 a20200331-exhibit991xearni.htm EXHIBIT 99.1 Exhibit 99.1 NeuroMetrix Reports Q1 2020 Financial Results WOBURN, Mass., April 23, 2020 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2020. The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chron
April 23, 2020	EX-10.1	Separation Agreement Francis X. McGillin March 12, 2020 EX-10.1 2 a10q3312020ex101.htm EXHIBIT 10.1 EXHIBIT 10.1 Separation Agreement Francis X. McGillin March 12, 2020 This Separation Agreement, including the release of claims, (the "Agreement") is made by and between Francis X. McGillin, an individual, and NeuroMetrix, Inc. a Delaware corporation ("NeuroMetrix"). WHEREAS, NeuroMetrix desires to provide Mr. McGillin with separation benefits to assist
April 10, 2020	DEFA14A	NURO / NeuroMetrix, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 16, 2020	DEFA14A	NURO / NeuroMetrix, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
March 16, 2020	DEF 14A	Proxy Statement for our Annual Meeting of Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
March 4, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Number
February 19, 2020	EX-10.1	Form 8-K NeuroMetrix, Inc. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement February 19, 2020 Ladenburg Thalmann & Co. Inc. 277 Park Avenue, 26th Floor New York, NY 10172 Ladies and Gentlemen: NeuroMetrix, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Agent”) as follows: 1.Issuance and Sale of Shares. The Company agrees
February 19, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
February 19, 2020	424B5	NEUROMETRIX, INC. Up to $2,200,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-229349 PROSPECTUS SUPPLEMENT (To Prospectus dated March 8, 2019) NEUROMETRIX, INC. Up to $2,200,000 Common Stock We have entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with Ladenburg Thalmann & Co. Inc., or Ladenburg, relating to our common stock, par value $0.0001 per share, offered by this prospectus supplement. I
January 28, 2020	EX-10.2.11	THIRTEENTH MODIFICATION TO LOAN AND SECURITY AGREEMENT THIRTEENTH MODIFICATION TO LOAN AND SECURITY AGREEMENT This Thirteenth Modification to Loan and Security Agreement (this "Modification") dated September 30, 21, 2019, is entered into by and between Neurometrix, Inc.
January 28, 2020	EX-10.2.12	FOURTEENTH MODIFICATION TO LOAN AND SECURITY AGREEMENT AND WAIVER FOURTEENTH MODIFICATION TO LOAN AND SECURITY AGREEMENT AND WAIVER This Fourteenth Modification to Loan and Security Agreement and Waiver (this "Modification") dated November 27, 2019, is entered into by and between Neurometrix, Inc.
January 28, 2020	EX-10.2.10	TWELFTH MODIFICATION TO LOAN AND SECURITY AGREEMENT TWELFTH MODIFICATION TO LOAN AND SECURITY AGREEMENT This Twelfth Modification to Loan and Security Agreement (this "Modification") dated June 21, 2019, is entered into by and between Neurometrix, Inc.
January 28, 2020	EX-10.14.3	ber 20, NEUROMetrix· December 20, 2019 Mr. Thomas T. Higgins Dear Torn, On behalf ofNeuroMetrix, Inc. (the "Company") and the Board of Directors, I offer you revised terms of e,nployment in your position as Chief Financial Officer as follows: • Effeclive date: January I, 2020 • Title & Responsibilities: Chief Financial Officer reporting to the Chief Executive Officer, overseeing the Company's Finance Depa
January 28, 2020	EX-10.2.9	ELEVENTH MODIFICATION TO LOAN AND SECURITY AGREEMENT ELEVENTH MODIFICATION TO LOAN AND SECURITY AGREEMENT This Eleventh Modification to Loan and Security Agreement (this "Modification") dated March 25, 2019, is entered into by and between Neurometrix, Inc.
January 28, 2020	EX-4.3.13	Amendment No. 12 to Shareholder Rights Agreement, dated January 27, 2020, between NeuroMetrix, Inc. and American Stock Transfer & Trust Company, as Rights Agent AMENDMENT NO. 12 TO SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 12 to Shareholder Rights Agreement (the “Amendment”), dated as of January 27, 2020, by and between NeuroMetrix, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC (the “Rights Agent”), amends that certain Shareholder Rights Agreement, dated as of March 7, 2007, as previously amended, bet
January 28, 2020	S-8	NURO / NeuroMetrix, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on January 27, 2020 REGISTRATION NO.
January 28, 2020	EX-10.2.13	FIFTEENTH MODIFICATION TO LOAN AND SECURITY AGREEMENT FIFTEENTH MODIFICATION TO LOAN AND SECURITY AGREEMENT This Fifteenth Modification to Loan and Security Agreement (this "Modification") dated January 23, 2020, is entered into by and between Neurometrix, Inc.
January 28, 2020	EX-10.13.4	, EX-10.13.4 9 a10k2019-2exhibit10134.htm EXHIBIT 10.13.4 NEUROMetrix· December 28, 2019 Mr. Shai N. Gozani - Dear Shai, On behalf of NeuroMetrix, Inc. (the "Company") and the Board of Directors, the Compensation Committee offers you revised tenns of employment in your position as President and Chief Executive Officer as follows: • Ejfecrive date: January 1, 2020 • Title & Responsibilities: Chief Ex
January 28, 2020	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33351 NEUROMETRIX, IN
January 28, 2020	EX-4.1	DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, NeuroMetrix, Inc. had three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) common stock, $0.0001 par value per share (“Common Stock”); (ii) rights to purchase shares o
January 28, 2020	EX-10.16.2	NEUROMETRIX, INC. Amended and Restated Management Retention and Incentive Plan NEUROMETRIX, INC. Amended and Restated Management Retention and Incentive Plan 1. Purpose of the Plan. The purpose of this Management Retention and Incentive Plan (the “Plan”) is to provide the executive officers and certain other key employees of NeuroMetrix, Inc., a Delaware corporation (the “Company”), listed on Schedule A hereto (the “Participants,” and each, a “Participant”) with consideratio
January 27, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 neurometrix-form8xkpressre.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2020 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdicti
January 27, 2020	EX-99.1	NeuroMetrix Reports Q4 and Full Year 2019 Financial Results Exhibit 99.1 NeuroMetrix Reports Q4 and Full Year 2019 Financial Results WOBURN, Mass., January 27, 2020 (Globe NewsWire) - NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and year ended December 31, 2019. The Company develops and commercializes diagnostic and therapeutic neurostimulation-based medical devices. The Company has three commercial prod
December 30, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2019 NEUROMETRIX, INC. (Exact name of registrant as specified in charter) Delaware 001-33351 04-3308180 (State or other jurisdiction of incorporation) (Commission File Nu
November 18, 2019	EX-3.1	Certificate of Amendment to Restated Certificate of Incorporation of NeuroMetrix, Inc. dated November 18, 2019 EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO EFFECT REVERSE STOCK SPLIT NeuroMetrix, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1.The name of the corporation (hereinafter called the “Corporation”) is NeuroMetrix, Inc. 2.The Corporation’s original Certificate of Incorporation was filed with the Secretary of State o

NURO / NeuroMetrix, Inc. - Documents déposés auprès de la SEC, rapport annuel, procuration

Statistiques de base

SEC Filings

SEC Filings (Chronological Order)